Vol. 23, No. 1, January 2000 (Supplement I)
J.H. CHESEBRO, M.D. and F.W.A. VERHEUGT, M.D., F.A.C.C., F.E.S.C., Guest Editors
Introduction: Expanding the Horizons in Unstable Coronary Artery Disease
James H. Chesebro, M.D. and Freek W.A. Verheugt, M.D., F.A.C.C., F.E.S.C.
Can We Differentiate the Low-Molecular-Weight Heparins?
Alexander G.G. Turpie, M.B., F.R.C.P. (Lond., Glasg.), F.A.C.P., F.A.C.C., F.R.C.P.C.
Acute Management -- How Should We Intervene?
Frederic Kontny, M.D., Ph.D.
Long-Term Management -- The Way Forward?
Lars Wallentin, M.D., Ph.D.
Targeting Treatment for Optimal Outcome
Steen E. Husted, M.D., D. Sci.
Proceedings from an international symposium organized at the XXIst Congress of the European Society of Cardiology, August 30, 1999, in Barcelona, Spain. Sponsored by an unrestricted educational grant from Pharmacia & Upjohn.
The editorial content of supplements is reviewed by the guest editor and approved by C. Richard Conti, M.D., Editor-in-Chief of the Journal. The findings presented in this supplement are those of the contributors and not necessarily those of the sponsor, the publisher, or the editors of Clinical Cardiology.
Clinical judgment must guide each physician in weighing the benefits of treatment against the risk of toxicity. References made in the articles may indicate uses of drugs at dosages, for periods of time, and in combinations not included in the current prescribing information.